<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920123</url>
  </required_header>
  <id_info>
    <org_study_id>2585</org_study_id>
    <nct_id>NCT04920123</nct_id>
  </id_info>
  <brief_title>Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic</brief_title>
  <official_title>Towards the Development of a Mobile-health Technology Designed to Encourage the Use of Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Amherst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Amherst</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the therapeutic efficacy of Neuro-World cognitive training games&#xD;
      (Woorisoft, S. Korea) in patients with mild cognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a cross-over randomized controlled trial.&#xD;
&#xD;
      Fifty participants will be enrolled and randomly assigned to group A or group B.&#xD;
&#xD;
      Group A will self-administer Neuro-World cognitive training games for 30 minutes a day, twice&#xD;
      a week for 12 weeks in the home setting (i.e., intervention period). For the following 12&#xD;
      weeks, the participants will not engage in any therapist-supervised cognitive therapies&#xD;
      (i.e., no-intervention period).&#xD;
&#xD;
      Group B will not engage in any therapist-supervised cognitive therapies (i.e.,&#xD;
      no-intervention period). For the following 12 weeks, the participants will self-administer&#xD;
      Neuro-World cognitive training games for 30 minutes a day, twice a week in the home setting&#xD;
      (i.e., intervention period).&#xD;
&#xD;
      All the participants in both groups will receive phone calls twice a week to 1) provide&#xD;
      feedback on their adherence to Neuro-World cognitive training (during the intervention&#xD;
      period) and 2) learn any significant changes in the level of their daily activities (during&#xD;
      the no-intervention period and the intervention period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>30 minutes</time_frame>
    <description>MoCA scores range between 0 and 30. Higher scores indicate better cognitive function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE)</measure>
    <time_frame>10 minutes</time_frame>
    <description>MMSE scores range between 0 and 30. Higher scores indicate better cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Forward Span (DFS)</measure>
    <time_frame>5 minutes</time_frame>
    <description>DFS scores range between 0 and 14. Higher scores indicate better cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Backward Span (DBS)</measure>
    <time_frame>5 minutes</time_frame>
    <description>DBS scores range between 0 and 14. Higher scores indicate better cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale (GDS)</measure>
    <time_frame>5 minutes</time_frame>
    <description>GDS scores range between 0 and 15. Higher scores indicate more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 (SF-36)</measure>
    <time_frame>10 minutes</time_frame>
    <description>SF-36 scores range between 0 and 100. Higher scores indicate more favorable health states.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for mild cognitive impairment patients (ADCS/MCI/ADL24)</measure>
    <time_frame>10 minutes</time_frame>
    <description>ADCS/MCI/ADL24 scores range between 0 and 69. Higher scores indicate greater levels of performance in activities of daily living.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Game Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study participants do not engage in any cognitive training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuro-World</intervention_name>
    <description>Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.</description>
    <arm_group_label>Game Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Twenty-four points or greater on the modified Telephone Interview for Cognitive Status&#xD;
             (TICS)&#xD;
&#xD;
          -  Eighteen years old and above&#xD;
&#xD;
          -  Minimal technological literacy (i.e. ability to use a tablet independently)&#xD;
&#xD;
          -  Having an active caregiver (necessary for technical support)&#xD;
&#xD;
          -  Having a computer for online videoconferencing-based communication (necessary for&#xD;
             online cognitive assessments)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confounding neurological and psychiatric disorders&#xD;
&#xD;
          -  History of traumatic brain injury&#xD;
&#xD;
          -  Clinically known hearing or vision impairment&#xD;
&#xD;
          -  Severe upper-limb motor impairments that could impact the use of mobile devices&#xD;
&#xD;
          -  Clinical presentations suggestive of dementia with Lewy bodies, progressive&#xD;
             supranuclear palsy, multiple system atrophy, or vascular parkinsonism&#xD;
&#xD;
          -  Diagnosis of dementia&#xD;
&#xD;
          -  Major depression&#xD;
&#xD;
          -  Any significant upper-limb impairment that could affect tablet use&#xD;
&#xD;
          -  Participation in any other therapist-supervised cognitive training&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunghoon I Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Amherst</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee-Tae Jung, PhD</last_name>
    <phone>413-835-5135</phone>
    <email>heetae@umass.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juhyeon Lee, MS</last_name>
    <phone>413-404-4732</phone>
    <email>juhyeonlee@cs.umass.edu</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

